Author: Valentina Fiori

 

The landscape of therapeutic antibodies is undergoing a significant transformation. For decades, the field was dominated by traditional monoclonal antibodies (mAbs), which revolutionized medicine by targeting single proteins involved in disease.

However, the current wave of innovation is moving beyond traditional monoclonal antibodies to more complex and highly targeted formats. The key trends are dominated by smarter, multi-functional molecules and the integration of Artificial Intelligence (AI) to accelerate their discovery.

A primary trend is the rapid ascent of complex, “non-canonical” antibody formats, particularly bispecific antibodies (bsAbs) and antibody-drug conjugates (ADCs), which now account for about 25% of new antibody approvals. Bispecific antibodies, capable of engaging two different targets simultaneously, are creating novel therapeutic mechanisms, especially in oncology, and are experiencing an accelerated pace of regulatory approvals.

Concurrently, ADCs are realizing their potential as “smart chemotherapy”, combining the specificity of an antibody with the potency of a cytotoxic payload to attack cancer cells while minimizing collateral damage. Innovation in ADC technology is focused on developing novel payloads, smarter linkers, and dual-targeting capabilities to overcome drug resistance and tumor heterogeneity.

Another key trend is the exploration of smaller antibody fragments, particularly nanobodies from camelids. These offer advantages like superior tissue penetration, high stability, and access to challenging epitopes, opening new treatment avenues for difficult-to-reach targets, including those in the central nervous system.

Underpinning all these advancements is the transformative impact of Artificial Intelligence (AI) and Machine Learning (ML). AI is revolutionizing the entire antibody discovery and engineering workflow, from predicting antibody structures and interactions to generating novel candidates with desired properties from scratch. This integration of computational power is dramatically reducing timelines, costs, and failure rates, accelerating the delivery of next-generation therapeutics to patients.

Emerging Trends Redefining Antibody Discovery and Design

1. The Rise of Multi-Specific Antibodies

The most prominent trend is the shift from monospecific antibodies (targeting one antigen) to multi-specific formats, especially bispecific antibodies (BsAbs).

Unlike traditional mAbs that bind to a single target, bsAbs are designed with two distinct binding domains, allowing them to simultaneously engage two different antigens or two different epitopes on the same antigen.

This dual-targeting capability unlocks novel mechanisms of action, such as physically bridging a T-cell to a cancer cell to trigger a targeted immune attack, or simultaneously blocking two separate disease-mediating pathways.

This area is expanding with recent and upcoming approvals, particularly in oncology. While only three bsAbs were approved by the end of 2020, at least 11 more have gained approval since then, with many achieving blockbuster status.

2024 saw first approvals for several bsAbs, including tarlatamab, zanidatamab, Odronextamab, and zenocutuzumab, with others like linvoseltamab expected to follow in 2025.

While oncology remains the dominant application (e.g., tarlatamab, zanidatamab, zenocutuzumab, linvoseltamab), their utility is expanding into non-oncology areas, with approved therapies like emicizumab for hemophilia A and faricimab for macular degeneration, and promising candidates in the pipeline for autoimmune and inflammatory disorders (e.g., sonelokimab).

2. The Resurgence of Antibody-Drug Conjugates (ADCs)

The ADC field is experiencing a resurgence, backed by heavy annual R&D investment.  As to date, 19 ADCs have received FDA/EMA approval for various solid tumors and hematologic malignancies and more than 200 ADCs are in clinical development.

The next wave of innovation is focused on enhancing every component of the ADC to improve its therapeutic index (the balance between efficacy and toxicity):

  • Novel Payloads: Developers are moving beyond traditional chemotherapy agents to incorporate new classes of payloads, including immune-stimulating agents (creating “immune-stimulating ADCs”) and protein degraders, which offer different mechanisms of action to combat resistance.
  • Advanced Linker Technology: The linker is crucial for an ADC’s success. Innovations are focused on creating more stable linkers that prevent premature release of the payload in the bloodstream. Some cleavable linkers are designed to release the payload in the tumor microenvironment, enabling a “bystander effect” where the drug can kill adjacent cancer cells that may not even express the target antigen.
  • Bispecific ADCs: To address tumor heterogeneity, where antigen expression can vary across cancer cells, researchers are developing ADCs based on bispecific antibodies. These can recognize two different tumor antigens, increasing the likelihood of binding to and destroying a wider range of cancer cells. In addition, Bispecific ADCs might be more tumor-specific, decreasing the off-target toxicity and might exert potential synergistic effects.

3. The Rise of Nanobodies

While much of the industry focuses on complex, full-sized antibodies, a parallel trend is emerging toward smaller, more versatile formats. At the forefront are nanobodies, the smallest known functional antibody fragments. Originally discovered in camelids (like camels and llamas), these unique molecules consist of a single heavy-chain variable domain (VHH) and offer a host of advantages over conventional mAbs.

Key Advantages of Nanobodies:

  • Size and Penetration: Their small size allows for superior penetration into dense tissues like tumors and in some cases they have been reported to be able to cross the blood-brain barrier, a major hurdle for most biologics. This opens up new therapeutic possibilities for brain cancers and neurological disorders.
  • Stability and Production: Nanobodies are remarkably robust, able to withstand extreme temperatures and pH levels. They can also be produced cost-effectively in microbial systems like bacteria or yeast.
  • Unique Target Binding: Their structure, featuring a long, finger-like CDR3 loop, enables them to bind to unique, concave epitopes, such as the active sites of enzymes, that are often inaccessible to larger, conventional antibodies.
  • Modularity: Their simple structure makes them ideal building blocks for creating more complex molecules, such as biparatopic nanobodies (targeting two epitopes on one antigen) or nanobody-drug conjugates.

These properties make nanobodies powerful tools for therapy, diagnostics, and in vivo imaging. While challenges such as their naturally short half-life remain, this can be overcome

4. AI and Machine Learning in Antibody Discovery

Artificial intelligence (AI) is rapidly moving from a buzzword to an essential tool in antibody development. AI is being used to overcome major bottlenecks in discovery and engineering.

  • Key Applications:
    • Target Discovery: AI algorithms can analyze massive biological datasets (genomics, proteomics) to identify novel and “difficult-to-drug” targets on diseased cells.
    • Antibody Design and Optimization: Machine learning models can predict how an antibody will fold and bind to its target in silico (on a computer). This allows for the rapid design and optimization of antibodies with high affinity and stability, dramatically cutting down on laboratory guesswork and development time.
    • Generative AI for De Novo Design: Moving beyond screening existing libraries, generative AI approaches can now design entirely novel antibody sequences or 3D structures tailored to bind a specific target with desired characteristics.
    • Impact: This trend is accelerating the entire drug discovery pipeline, making it faster and more cost-effective to move a promising candidate from a concept to clinical trials.22

 

Valentina Fiori holds a PhD in Biochemical and Pharmacological Sciences, and is Biologics R&D Manager at Diatheva, where she leads the development of therapeutic recombinant monoclonal antibodies targeting oncology and infectious diseases. She combines scientific strategy with industrial collaboration, managing complex R&D programs that bridge academic innovation and biopharmaceutical application.

 

References